The FDA approved Mimrylo (rusfertide) for polycythemia vera, clearing Takeda’s first-in-class therapy developed by Protagonist Therapeutics. Takeda’s broader-than-expected label gives the drug a potential revenue runway as the company balances product growth ahead of patent expirations tied to older franchises. Mimrylo is a weekly injectable therapy aimed at reducing excess red blood cell production in polycythemia vera. The clearance also represents a second FDA win for Protagonist, which now strengthens its commercialization path through a major partner. Analysts will now focus on uptake, payer coverage dynamics, and how the label positions Mimrylo against existing standards of care for PV-related thrombosis risk and symptom burden.